Treuner J, Klingebiel T, Bruchelt G, Feine U, Niethammer D
Department of Pediatric Hematology, University Hospital, Tübingen, Federal Republic of Germany.
Med Pediatr Oncol. 1987;15(4):199-202. doi: 10.1002/mpo.2950150412.
Between April 1984 and December 1985 we treated ten children suffering from neuroblastoma in a total of 25 metaiodobenzylguanidine (MIBG) courses. Five had had a relapse of neuroblastoma stage III or IV, three had never achieved a remission in spite of intensive chemotherapy, and two were treated with an unstable remission. The children were each administered from 1 to 5 courses with a dosage per course of between 1,295 and 9,065 MBq. The sum of the single doses during the whole course of therapy ranged between 3,145 and 21,904 MBq per child. Five of five children suffering from bone pain and fever became free of complaints during the first three treatment days. Six of eight children with manifest tumor at onset of therapy responded well to the treatment: response extended from transitory decrease in elevated catecholamine levels in serum and urine to complete disappearance of large abdominal tumor masses. We also observed a decrease in bone marrow involvement and a stabilization of osteolytic lesions. Seven of these eight children died in spite of a good response from 55 to 350 days after the first MIBG treatment course. The only side effect we witnessed was a reversible bone marrow depression. In three children we combined the MIBG therapy with bone marrow transplantation.
1984年4月至1985年12月期间，我们共对10名患有神经母细胞瘤的儿童进行了25个间碘苄胍（MIBG）疗程的治疗。其中5名儿童为神经母细胞瘤III期或IV期复发，3名儿童尽管接受了强化化疗仍未实现缓解，另外2名儿童处于病情不稳定的缓解期。每个儿童接受了1至5个疗程的治疗，每个疗程的剂量在1295至9065 MBq之间。每个儿童在整个治疗过程中的单次剂量总和在3145至21904 MBq之间。5名患有骨痛和发热的儿童中有5名在治疗的前三天内症状消失。8名在治疗开始时出现明显肿瘤的儿童中有6名对治疗反应良好：反应范围从血清和尿液中儿茶酚胺水平的短暂下降到腹部大肿瘤块的完全消失。我们还观察到骨髓受累情况有所减轻，溶骨性病变趋于稳定。这8名儿童中有7名尽管在首次MIBG治疗疗程后55至350天反应良好，但仍死亡。我们所观察到的唯一副作用是可逆性骨髓抑制。在3名儿童中，我们将MIBG治疗与骨髓移植相结合。
